Moderna trims top end of full-year forecast on weak COVID vaccine sales
Moderna(US:MRNA) Reuters·2025-11-06 20:11Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of its COVID-19 vaccine in the U.S. as Americans struggled to access the shots. ...